Retraction

Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells

Retraction Details

Nature of Retraction:

Retraction

Retraction Notice:
10.3892/ol.2023.13938
Additional Notes:

see also: https://pubpeer.com/publications/7F428D3100D3E737126753BC96ABA8

Citations (13)

13
Total Citations
4
Post-Retraction
(30.8%)
9
Pre-Retraction
0
Same Day
Post-Retraction Citation Analysis
0 Within 30 days
4 Within 1 year
0 After 2+ years
296 Days since retraction (latest)
Guidelines for the role of autophagy in drug delivery vectors uptake pathways
Moataz Dowaidar
Heliyon Open Access
Published: Apr 2024
296 days after retraction
The SMAC mimetic GDC-0152 is a direct ABCB1-ATPase activity modulator and BIRC5 expression suppressor in cancer cells
I‐Li Lin, Yu-Ting Lin, Yung-Chieh Chang et al. (9 authors)
Toxicology and Applied Pharmacology
Published: Mar 2024
3 citations
246 days after retraction
Targeting mTOR and Survivin Concurrently Potentiates Radiation Therapy in Renal Cell Carcinoma by Suppressing DNA Damage Repair and Amplifying Mitotic Catastrophe
Hari K. Rachamala, Vijay Sagar Madamsetty, Ramcharan Singh Angom et al. (8 authors)
Research Square (Research Square) Open Access
Published: Dec 2023
3 citations
173 days after retraction
ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer
Elena Farmaki, Aritro Nath, Rena Emond et al. (7 authors)
eLife Open Access
Published: Sep 2023
6 citations
88 days after retraction
In Vitro Effects of Combining Genistein with Aromatase Inhibitors: Concerns Regarding Its Consumption during Breast Cancer Treatment
Patrícia Heloise Alves Bezerra, Cristina Amaral, Cristina Ferreira Almeida et al. (6 authors)
Molecules Open Access
Published: Jun 2023
4 citations
12 days before retraction
ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer
Elena Farmaki, Aritro Nath, Rena Emond et al. (7 authors)
bioRxiv (Cold Spring Harbor Laboratory) Open Access
Published: Dec 2022
188 days before retraction
Emerging Roles for Mammalian Target of Rapamycin (mTOR) Complexes in Bladder Cancer Progression and Therapy
Jianya Huan, Petros Grivas, Jasmine Birch et al. (4 authors)
Cancers Open Access
Published: Mar 2022
33 citations
472 days before retraction
Inhibition of Breast Cancer Proteins by the Flavonoid Naringenin and its Derivative: A Molecular Docking Study
S Muralidharan, Antony Joseph Velanganni Arockiam, Kumaran Shanmugam
Journal of Natural Remedies Open Access
Published: Feb 2022
3 citations
504 days before retraction
Luminal A breast cancer resistance mechanisms and emerging treatments
Deborah H. Anderson
Elsevier eBooks
Published: Jan 2021
6 citations
913 days before retraction
Growth inhibitory efficacy and anti‑aromatase activity of Tabebuia avellanedae in a model for post‑menopausal Luminal A breast cancer
Nitin Telang, Hareesh B. Nair, George Y. Wong
Biomedical Reports Open Access
Published: Oct 2019
10 citations
1369 days before retraction
Autophagy Modulators: Mechanistic Aspects and Drug Delivery Systems
Shima Tavakol, Milad Ashrafizadeh, Shuo Deng et al. (14 authors)
Biomolecules Open Access
Published: Sep 2019
71 citations
1377 days before retraction
The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2− Metastatic Breast Cancer: Biological Mechanisms and New Treatments
Daniele Presti, Erica Quaquarini
Cancers Open Access
Published: Aug 2019
95 citations
1409 days before retraction
[Expressions of survivin, PI3K and AKT in keratinocytes in skin lesions and their pathogenic role in psoriasis vulgaris].
Hao Wang, Liwei Ran, Ke Hui et al. (5 authors)
PubMed
Published: Nov 2017
10 citations
2051 days before retraction